Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
59 hedge funds and large institutions have $214M invested in Ra Pharmaceuticals, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$47.5M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$27.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.4M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$11.2M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
STRS Ohio
Columbus,
Ohio
| $39K | +$35.3K | +2,600 | New |
|
52
UBS Group
Zurich,
Switzerland
| $36K | +$32.5K | +2,391 | New |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $34K | +$30.2K | +2,220 | New |
|
54
Legal & General Group
London,
United Kingdom
| $19K | +$16.9K | +1,245 | New |
|
|
BJ
55
BlackRock Japan
Tokyo,
Japan
| $15K | +$13.4K | +984 | New |
|
|
FPFS
56
First Personal Financial Services
Charlotte,
North Carolina
| $9K | +$8.25K | +607 | New |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | +$6.73K | +495 | New |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| $1K | +$924 | +68 | New |
|
59
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$313 | +23 | New |
|
RARX Hedge Fund Activity: Q4 2016 in Review
59 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q4 2016, worth a combined $214M.
Buyers outnumbered sellers: 59 funds opened new RARX positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $47.5M.
- 59 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $214M of Ra Pharmaceuticals, Inc. Common Stock stock for Q4 2016.
- 59 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q4 2016 and 0 closed out, a net change of +59 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q4 2016 was NEA Management Company, an estimated $47.5M added.
Based on aggregated 13F filings for Q4 2016.